Sanofi: Genzyme expands collaboration with Alnylam

BUY, Fair Value EUR88,5 (+20%)

News published on January Monday 13, 2014
Share on

Sanofi and Alnylam have inked a wide collaborative agreement which gives Genzyme expanded access to Alnylam’s pipeline that is targeting several rare genetic diseases. Rights in NA and Europe are usually either excluded or shared however. Genzyme is making a USD700m investment in Alnylam. It is too early to adjust our model as the opportunity is more medium term.  


Full report available to subscribers
Please contact marketing@bryangarnier.fr   

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities